Horsted F, West J, Grainge MJ. Risk of venous thromboembolismin patients with cancer: A systematic review and meta-analysis. PLoS Med. 2012;9(7):e1001275.
DOI: 10.1371/journal.pmed.1001275
Frere C, Connors JM, Farge D. Management of Cancer-Associated Thrombosis: An Evolving Area. Cancers (Basel) 2020;12(10):2999.
DOI: 10.3390/cancers12102999
Ording AG, Skjøth F, Søgaard M, Højen AA, Overvad TF, Noble S, et al. Increasing incidence and declining mortality after cancer-associated venous thromboembolism-national wide cohort study. Am J Med. 2021:S0002-9343(21)00114-5.
Francis CW, Kessler CM, Goldhaber SZ, Kovacs MJ, Monreal M, Huisman MV, et al. Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12 months: the DALTECAN Study. J Thromb Haemost 2015;13(6):1028-35.
DOI: 10.1111/jth.12923
Lozano Sánchez FS. Nuevos anticoagulantes orales en el tratamiento de la trombosis venosa profunda. Angiología 2012;64(5):212-7.
DOI: 10.1016/j.angio.2012.04.002
Lozano Sánchez F. Anticoagulantes orales directos. En Notas históricas sobre la trombosis venosa. Lozano F (editor). Salamanca: Kadmos; 2015. p. 79-85.
Trousseau A. Ulcere chronique simple de l’estomac. Clin Med Hop Dieu de Paris. Paris: J-B Balliere et fils 1865(3).
Sproul EE. Carcinoma and venous thrombosis: frequency of association of carcinoma in body or tail of pancreas with multiple venous thrombosis. Am J Cancer 1938;34:566-85.
Mandala M, Reni M, Cascinu S, Barni S, Floriani I, Cereda S, et al. Venous thromboembolism predicts poor prognosis in irresectable pancreatic cancer patients. Ann Oncol 2007;18(10):1660-15.
DOI: 10.1093/annonc/mdm284
Fuentes HE, Oramas DM, Paz LH, Wang Y, Andrade XA, Tafur AJ. Venous thromboembolism is an independent predictor of mortality among patients with gastric cancer. J Gastrointest Cancer 2018;49(4):415-21.
DOI: 10.1007/s12029-017-9981-2
Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008;111(10):4902-7.
DOI: 10.1182/blood-2007-10-116327
Ghukasyan R, Donahue TR. Cancer-Related Venous Thromboembolism as a Complication and Negative Prognostic Factor. Gastroenterology 2020;158(5):1214-5.
DOI: 10.1053/j.gastro.2020.02.017
Carrier M, Abou-Nassar K, Mallick R, Tagalakis V, Shivakumar S, Schattner A, et al. Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med 2019;380(10):711-9.
DOI: 10.1056/NEJMoa1814468
Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T, et al. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med 2019;380(8):720-8.
DOI: 10.1056/NEJMoa1814630
Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, et al; RE-COVER study group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009;361(24):2342-52.
DOI: 10.1056/NEJMoa0906598
Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P, et al; RE-COVER II trial investigators. Treatment of acute venous thromboembolism with dabigatran or
EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Eng J
Med 2010;363:(26)2499-510.
EINSTEIN-PE Investigators; Büller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012;366(14):1287-97.
DOI: 10.1056/NEJMoa1113572
Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al; the AMPLIFY investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J
Med 2013(9);369:799-808.
Hokusai-VTE Investigators, Büller HR, Décousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, et al. Edoxaban versus warfarin for the treatment of symptomatic venous
Schulman S, Kearon C, Kakkar AK, Schellong S, Eriksson H, Baanstra D, et al; RE-MEDY trial investigators; RE-SONATE trial investigators. Extended use of dabigatran, warfarin,
Weitz JI, Lensing AWA, Prins MH, Bauersachs R, Beyer-Westendorf J, Bounameaux H, et al. EINSTEIN CHOICE
investigators. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med 2017;376(13):1211-22.
DOI: 10.1056/NEJMoa1700518
Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, et al; AMPLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J
Med 2013;368 (8):699-708.
Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018;378(7):615e24.
DOI: 10.1056/NEJMoa1711948
Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018;36(20):2017e23.
DOI: 10.1200/JCO.2018.78.8034
McBane II R, Wysokinski WE, Le-Rademacher JG, Zemla T, Ashrani A, Tafur A, et al. Apixaban and dalteparin in active malignancy associated venous thromboembolism: the
Agnelli G, Becattini C, Meyer G, Muñoz A, Huisman MV, Connors JM, et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 2020;382(17):1599e607.
DOI: 10.1056/NEJMoa1915103
Carrier M, Cameron C, Delluc A, Castellucci L, Khorana AA, Lee AY. Efficacy and safety of anticoagulant therapy for the treatment of acute cancer-associated thrombosis: a systematic review and meta-analysis. Thromb Res 2014;134(6):1214-9.
DOI: 10.1016/j.thromres.2014.09.039
Posch F, Königsbrügge O, Zielinski Ch, Pabinger I, Ay C. Treatment of venous thromboembolism in patients with cancer: A network meta-analysis comparing efficacy and safety of anticoagulants. Thromb Res 2015;136(3):582-9.
DOI: 10.1016/j.thromres.2015.07.011
Vedovati MC, Germini F, Agnelli G, Becattini C. Direct oral anticoagulants in patients with VTE and cancer: a systematic review and meta-analysis. Chest 2015;147(2):475-83.
DOI: 10.1378/chest.14-0402
Di Minno MND, Ageno W, Lupoli R, Conte G, van Es N, Buller HR, et al. Direct oral anticoagulants for the treatment of acute venous thromboembolism in patients with cancer: a meta-analysis of randomised controlled trials. Eur Respir J 2017;50(3):1701097.
DOI: 10.1183/13993003.01097-2017
Al Yami MS, Badreldin HA, Mohammed AH, Elmubark AM, Alzahrani MY, Alshehri AM. Direct oral anticoagulants for the treatment of venous thromboembolism in patients with active malignancy: a systematic review and meta-analysis. J Thromb Thrombolysis 2018;46(2):145-53.
DOI: 10.1007/s11239-018-1696-0
Sobieraj DM, Baker WL, Smith E, Sasiela K, Trexler SE, Kim O, et al. Anticoagulation for the Treatment of Cancer-Associated Thrombosis: A Systematic Review and Network Meta-Analysis of Randomized Trials. Clin Appl Thromb Hemost 2018;24(9 suppl):182S-7S.
DOI: 10.1177/1076029618800792
Vedovati MC, Giustozzi M, Bonitta G, Agnelli G, Becattini C. Efficacy and safety of anticoagulant agents in patients with venous thromboembolism and cancer: A network meta-analysis. Thromb Res 2018;170:175-80.
DOI: 10.1016/j.thromres.2018.08.023
Dong Y, Wang Y, Ma RL, Liu M, Gao JZ, Su WY, et al. Efficacy and safety of direct oral anticoagulants versus low-molecular-weight heparin in patients with cancer: a systematic review and meta-analysis. J Thromb Thrombolysis 2019;48(3):400-12.
DOI: 10.1007/s11239-019-01871-4
Fuentes HE, McBane 2nd RD, Wysokinski WE, Tafur AJ, Loprinzi ChL, Murad MH, et al. Direct Oral Factor Xa Inhibitors for the Treatment of Acute Cancer-Associated Venous
Kirkilesis GI, Kakkos SK, Tsolakis IA. Editor’s Choice-A systematic review and meta-analysis of the efficacy and safety of anticoagulation in the treatment of venous
thromboembolism in patients with cancer. Eur J Vasc Endovasc Surg 2019;57(5):685-701.
Li A, García DA, Lyman GH, Carrier M. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis. Thromb Res 2019;173:158-63.
DOI: 10.1016/j.thromres.2018.02.144
Rossel A, Robert-Ebadi H, Combescure C, Grosgurin O, Stirnemann J, Addeo A, et al. Anticoagulant therapy for acute venous thrombo-embolism in cancer patients: A systematic review and network meta-analysis. PLoS One 2019;14(3):e0213940.
DOI: 10.1371/journal.pone.0213940
Wang Y, Lv H, Li D, Chen C, Gu G, Sun Y, et al. Efficacy and Safety of Direct Oral Anticoagulants for Secondary Prevention of Cancer-Associated Thrombosis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials and Prospective Cohort Studies. Front Pharmacol 2019;10:773.
DOI: 10.3389/fphar.2019.00773
Yang M, Li J, Sun R, Wang Y, Xu H, Yang B, et al. Comparison between direct factor Xa inhibitors and low-molecular-weight heparin for efficacy and safety in the treatment of cancer-associated venous thromboembolism: A meta-analysis. J Cancer Res Ther 2019;15(7):1541-6.
DOI: 10.4103/jcrt.JCRT_68_19
Bhatia K, Uberoi G, Bajaj NS, Jain V, Arora S, Tafur A, et al. Meta-Analysis Comparing Direct Oral Anticoagulants to Low Molecular Weight Heparin for Treatment of Venous Thromboembolism in Patients With Cancer. Am J Cardiol 2020;133:175-8.
DOI: 10.1016/j.amjcard.2020.07.027
Desai A, Gyawali B. Assessing the benefits and harms of direct oral anticoagulants in patients with cancer for the prophylaxis and treatment of venous thromboembolism: a systematic review and meta-analysis. Ecancermedicalscience 2020;14:1091.
DOI: 10.3332/ecancer.2020.1091
Desai R, Koipallil GK, Thomas N, Mhaskar R, Visweshwar N, Laber D, et al. Efficacy and safety of direct oral anticoagulants for secondary prevention of cancer associated thrombosis: a meta-analysis of randomized controlled trials. Sci Rep 2020;10(1):18945.
DOI: 10.1038/s41598-020-75863-3
Giustozzi M, Agnelli G, del Toro-Cervera J, Klok FA, Rosovsky RP, Martin AC, et al. Direct oral anticoagulants for the treatment of acute venous thromboembolism associated with cancer: A systematic review and meta-analysis. Thromb Haemost 2020;120(7):1128-36.
DOI: 10.1055/s-0040-1712098
Mai V, Tanguay VF, Guay CA, Bertoletti L, Magnan S, Turgeon AF, et al. DOAC compared to LMWH in the treatment of cancer related-venous thromboembolism: a systematic
Moik F, Posch F, Zielinski C, Pabinger I, Ay C. Direct oral anticoagulants compared to low-molecular-weight heparin for the treatment of cancer-associated thrombosis: Updated
systematic review and meta-analysis of randomized controlled trials. Res Pract Thromb Haemost 2020;4(4):550-61.
DOI: 10.1002/rth2.12359
Mulder FI, Bosch FTM, Young AM, Marshall A, McBane RD, Zemla TJ, et al. Direct oral anticoagulants for cancer-associated venous thromboembolism: a systematic review and meta-analysis. Blood 2020;136(12):1433-41.
DOI: 10.1182/blood.2020005819
Samaranayake CB, Anderson J, McCabe C, Zahir SF, Upham J, Keir G. Direct oral anticoagulants for cancer-associated venous thromboembolisms: a systematic review and network meta-analysis. Intern Med J 2020;8.
Sidahmed S, Abdalla A, Kheiri B, Bala A, Salih M, Bachuwa G, et al. Anticoagulants for the treatment of venous thromboembolism in patients with cancer: A comprehensive systematic review, pairwise and network meta-analysis. Crit Rev Oncol Hematol 2020;152:103005.
DOI: 10.1016/j.critrevonc.2020.103005
Yan YD, Ding Z, Pan MM, Xia Q, Cui JJ, Wang LW, et al. Net clinical benefit of direct oral anticoagulants in patients with cancer and venous thromboembolism: A systematic
review and trade-off analysis. Front Cardiovasc Med 2020;7:586020.
Dong S, Zhang Y, Li Y, Li Y, Miao Y, Zhao R, et al. Direct oral anticoagulant for the treatment of VTE in cancer patients: A systematic review and meta-analysis. Ann Pharmacother
2021;55(4):430-9.
Song X, Liu Z, Zeng R, Shao J, Liu B, Zheng Y, et al. Treatment of venous thromboembolism in cancer patients: a systematic review and meta-analysis on the efficacy and safety of different direct oral anticoagulants (DOACs). Ann Transl Med 2021;9(2):162.
DOI: 10.21037/atm-20-8156
Kearon C, Akl EA, Ornelas J, Blaivas A, Jiménez D, Bounameaux H, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest 2016;149(2):315-52.
DOI: 10.1016/j.chest.2015.11.026
Kakkos SK, Gohel M, Baekgaard N, Bauersachs R, Bellmunt-Montoya S, Black SA, et al. Editor’s Choice-European Society for Vascular Surgery (ESVS) 2021 Clinical Practice
Guidelines on the Management of Venous Thrombosis. Eur J Vasc Endovasc Surg 2021;61(1):9-82.
Farge D, Frere C, Connors JM, Ay C, Khorana AA, Muñoz A, et al; International Initiative on Thrombosis and Cancer (ITAC) advisory panel. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol 2019;20(10):e566-e81.
DOI: 10.1016/S1470-2045(19)30750-8
Khorana AA, Noble S, Lee AYY, Soff G, Meyer G, O’Connell C, et al. Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. Thromb Haemost 2018;16(9):1891-4.
DOI: 10.1111/jth.14219
Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Clinical Practice Guideline Update. J Clin Oncol 2020;38(5):496-520.
DOI: 10.1200/JCO.19.01461
Lyman GH, Carrier M, Ay C, Di Nisio M, Hicks LK, Khorana AA, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv 2021;5(4):927-74.
DOI: 10.1182/bloodadvances.2020003442
Pernod G, Joly M, Sonnet B. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for the treatment of cancer-associated thrombosis (which agent for which patient). J Med Vasc 2020;45(6S):6S17-23.
DOI: 10.1016/S2542-4513(20)30515-0
Número de descargas:
9449
Número de visitas:
2015
Citas:
0
